Sir,

At the outset, we take the opportunity to congratulate the editorial team for the timely editorial "Are we moving towards a new definition of essential medicines?" by Manikandan published in your reputed journal.\[[@ref1]\] The World Health Organization (WHO) published the first essential medicines list in 1977 and since then, the list has been revised every 2 years. The current one is the 19^th^ model list published in April 2015. The importance of essential medicine list of WHO lies in the fact that it serves as a model for the development of national and institutional essential medicine list. There is paucity of criticism on WHO essential medicine list and in this perspective, the present editorial stands as a welcome initiative.

The editorial mentioned alcohol-based hand rubs are not superior to soap and water, but are more expensive.\[[@ref1]\] In this regard, WHO suggested that alcohol-based hand rubs are quick, simple, efficient, and handy and fulfill the highest standards of safety in relation to the prevention of cross-infection.\[[@ref2]\] Further, majority (90%) of studies also suggested that alcohol-based hand rubs are superior to soap and water hand washing and, hence, should be used as the first choice for hand hygiene (for non-soiled hands) whenever available.\[[@ref2]\]

The editorial also mentioned that daclatasvir and dasabuvir are investigational agents for treatment of hepatitis C infection that find a place in the 19^th^ Model List of Essential Medicines.\[[@ref1]\] This brings to notice that daclastvir and dasabuvir have been already approved by the US Food and Drug Administration (US FDA) and the European Medicines Agency (EMEA) to treat hepatitis C virus (HCV) infections.\[[@ref3][@ref4][@ref5][@ref6]\]

The editorial also stated that the drug bedaquiline (for multidrug-resistant tuberculosis) has not been registered by any drug regulatory authority as yet.\[[@ref1]\] However, bedaquiline was approved by the USFDA in December 2012 for the treatment of adults with multidrug-resistant pulmonary tuberculosis for whom an effective treatment regimen is not otherwise available.\[[@ref7]\] On Dec 20, 2013, the EMEA\'s Committee for Medicinal Products for Human Use (CHMP) also granted a conditional marketing authorization for bedaquiline for use as part of a combination therapy for pulmonary multidrug-resistant tuberculosis in adult patients.\[[@ref8]\] In a recent commentary in the Bulletin of WHO, Magrini *et al*. advocated the inclusion of bedaquiline owing to the public health relevance and severity of the condition and the lack of alternative treatment options.\[[@ref9]\]

This editorial invites further scrutiny of the WHO essential medicines list 19^th^ version, which may prove beneficial for shaping our own National Essential Medicines List which is currently in the process of development.
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